Clearside Biomedical Plunges 10.43% Amid Volatility

On July 24, 2025, Clearside Biomedical's stock experienced a significant drop of 10.43% in pre-market trading.

Clearside Biomedical's stock has been volatile in recent trading sessions. On July 22, 2025, the stock price increased by 3.66%, rising from $0.339 to $0.351. This volatility is likely due to the company's recent developments and market sentiment.

One of the key drivers behind the recent volatility is the approval of XIPERE by Health Canada for the treatment of uveitic macular edema. This approval has expanded the medication's availability and has been a significant catalyst for the stock's performance. The stock surged 51% following this news, indicating strong investor interest in the company's pipeline for eye conditions.

Analysts have also weighed in on the stock, with an average rating of "Hold" and a 12-month stock price target of $4.33, which represents a significant increase from the current price. This target reflects the potential upside in the stock, driven by the company's pipeline and market opportunities.